Rapiscan® Systems, a leading global supplier of security inspection technology, today announced that its 920CT checkpoint screening system has achieved C3 approval from the European Civil Aviation Conference (ECAC) under its Common Evaluation Process (CEP) for Explosive Detection Systems for Cabin Baggage (EDSCB).

It was announced today that the Coalition for Epidemic Preparedness Innovations (CEPI) and CureVac AG, a biopharmaceutical company pioneering the field of mRNA-based vaccines, have announced a partnership agreement worth up to US$ 34 million for the ongoing development of The RNA Printer prototype—a transportable, down-scaled, automated messenger RNA (mRNA) printing facility. This innovative platform will provide a rapid supply of lipid-nanoparticle (LNP)-formulated mRNA vaccine candidates that can target known pathogens (including Lassa Fever, Yellow Fever, and Rabies) and prepare for rapid response to new and previously unknown pathogens (referred to by WHO as “Disease X”).